TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01675661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
Study: NCT03101982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBO
Description: Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
Study: NCT04628520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen matrix
Description: After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance
Description: Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance
Description: Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Maintenance
Description: Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
Study: NCT03113617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study: NCT02279693

Intervention type: OTHER
Group type: OTHER
Intervention: CBCT
Description: 10 participants will receive a cone beam computed tomography (CBCT) repositioning

Intervention type: OTHER
Group type: OTHER
Intervention: fiducial marker (kV imaging)
Description: 10 participants will receive a kV imaging of fiducial marker repositioning.

Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT Associated With IMRT

Intervention type: RADIATION
Group type: OTHER
Intervention: IGRT Associated With IMRT
Study: NCT03113617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00562575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01429116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
Study: NCT00943267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha
Description: Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0.9%)
Description: Normal saline is given intrabronchially by bronchoscopy at t=0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling is done by venapuncture at t=0 and t=6

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling is done by venapuncture at t=0 and t=6
Study: NCT04545060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
Study: NCT03723941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Etoposide
Description: Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl.
Study: NCT01191983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
Study: NCT00749736

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: doxercalciferol
Description: 1 mcg of doxercalciferol per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm.
Study: NCT02657733

Intervention type: DEVICE
Group type: OTHER
Intervention: Radical-7
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa).
Study: NCT03599830

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive test passations
Description: Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences
Study: NCT03596151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Click Device
Description: A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
Study: NCT02657733

Intervention type: DEVICE
Group type: OTHER
Intervention: Nellcor™ Bedside Respiratory Patient Monitoring System
Description: Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi).

Intervention type: DEVICE
Group type: OTHER
Intervention: Capnostream 20p
Description: Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
Study: NCT02290470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).
Study: NCT03258073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical simulation using scenario execution
Description: Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
Study: NCT00328016

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Guided Breathing
Description: The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE
Description: The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
Study: NCT02835781

Intervention type: OTHER
Intervention: Acellular dermal matrix implantation
Description: Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
Study: NCT04053686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaks
Description: 3-min breaks every half hour at work
Study: NCT00627315

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: NOTE: Surgery will not be paid by the study

Intervention type: PROCEDURE
Intervention: Gastric banding
Description: NOTE: Surgery will not be paid by the study
Study: NCT02781870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LiquiBand Fix8 glue fixation
Description: Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No-fixation
Description: Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
Study: NCT05710939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Study: NCT02402114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 120 mg Hydrocortisone given orally one time.
Study: NCT03723941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation or Mitotane
Description: Observation or mitotane alone according to the investigator's preference
Study: NCT02290470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: * Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
Study: NCT03723941

Intervention type: OTHER
Group type: OTHER
Intervention: Observation or Mitotane
Description: Observation or mitotane alone according to the investigator's preference
Study: NCT02290470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
Description: all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
Study: NCT01675999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative simplified FOLFOX-4 chemotherapy
Description: Preoperative chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative FOLFOX4+Cetuximab chemotherapy
Description: Preoperative chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Surgery followed by FOLFOX4 chemotherapy
Description: Preoperative chemotherapy
Study: NCT03795623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice-Weaning
Description: Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Study: NCT02858284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TUG
Description: Therapeutic Ultrasound for Glaucoma

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT04679558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish added to the preventive protocol
Description: Antibacterial agent varnish added to the preventive protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preventive protocol
Description: Preventive protocol
Study: NCT00879983

Intervention type: DRUG
Group type: OTHER
Intervention: azithromycin (Zithromax)
Description: 1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg

Intervention type: DRUG
Group type: OTHER
Intervention: azithromycin (Zithromax)
Description: 1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g
Study: NCT01282567

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
Study: NCT02178163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02284022

Intervention type: DEVICE
Intervention: Brain computer interface
Description: Recording the P300 Testing the device Using the device with a speller
Study: NCT01244204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Daily dose of 800IU of vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing capsules
Study: NCT04242459

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
Study: NCT01946659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence to Sleep Apnea Treatment
Description: A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Group
Description: The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
Study: NCT01316458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571 (Glivec®)
Study: NCT04633135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips stove
Description: Philips Smokeless stove HD4012LS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips stove
Description: Philips Smokeless stove HD4012LS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gyapa stove
Description: Wood stove made in Ghana

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gyapa stove
Description: Wood stove made in Ghana
Study: NCT03926910

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of hypovolemia using a ventricular stimulation without atrial pacing
Description: Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed.
Study: NCT04463537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body Temperature Measurements
Description: measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form.
Study: NCT01053507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan/naproxen sodium
Description: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Study: NCT03804242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience
Description: This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
Study: NCT02703142

Intervention type: PROCEDURE
Intervention: Patients after esophagectomy
Description: postoperative endoscopic evaluation
Study: NCT01101893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: raltegravir 400mg q12h x 5 days (Reference Treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: GSK2248761 200mg q24h x 5 days (Reference Treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761 + Raltegravir
Description: GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
Study: NCT03118505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infuse Bone Graft
Description: Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infuse Bone Graft
Description: Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infuse Bone Graft
Description: Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic DBM
Description: Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
Study: NCT03976050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
Study: NCT02692963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Description: BCG vaccine InterVax